Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial
Authors' conclusion
Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.
Study context
- Population
- US adults meeting SELECT trial inclusion criteria (secondary prevention of CVD), NHANES4,473,681 US adults
- Participants
- 216 participants
- Exposure
- Semaglutide 2.4 mg SC weekly vs no semaglutide
- Outcome
- Number of MACE (nonfatal MI, nonfatal stroke or CV death) and all-cause deaths potentially prevented
- Follow-up
- 4 years
Methodological detailsnationally representative, NHANES 2017-2018 and 2019-March 2020
- Nationally representative
- NHANES 2017-2018 and 2019-March 2020
Main finding
As reported in the abstract
MACE and all-cause mortality events
| Group | Major cardiovascular events (MACE) expected | All-cause mortality events expected | MACE prevented | All-cause mortality events prevented |
|---|---|---|---|---|
| No semaglutide | 356,329 | 232,808 | ||
| 50% uptake of semaglutide | 35,633 | 22,117 |
Major cardiovascular events (MACE) expected
No semaglutide356,329
50% uptake of semaglutide— not stated in the abstract
All-cause mortality events expected
No semaglutide232,808
50% uptake of semaglutide— not stated in the abstract
MACE prevented
No semaglutide— not stated in the abstract
50% uptake of semaglutide35,633
All-cause mortality events prevented
No semaglutide— not stated in the abstract
50% uptake of semaglutide22,117
Observational data: associations, not effects.
Original publication
Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial. Am Heart J. Published 30 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →